The earnings call highlighted significant positive developments such as successful trial results and a strong financial position. However, challenges in statistical power for the anorexia study and regulatory uncertainties were noted. Overall, the positive achievements in clinical trials and financial stability suggest an optimistic outlook.

Company Guidance -

Q3 2025

During the COMPASS Pathways Second Quarter 2025 Earnings Conference Call, the company provided several key metrics and updates. Notably, they reported cash and cash equivalents of $222 million as of the end of June, which they expect to fund operations into 2027. The company's debt under the Hercules loan facility stood at $30.9 million at the end of the second quarter. They also disclosed that cash used in operations for the second quarter was $38.7 million, with an expectation of net cash used in operations for the full year 2025 to range between $120 million and $145 million. Additionally, the company highlighted the successful achievement of the primary endpoint in their COMP360, 005 trial with a 3.6-point difference from baseline in mattress scores between the 25-milligram and placebo arms at 6 weeks, surpassing the 3-point threshold considered both clinically meaningful and commercially viable. They reaffirmed their commitment to advancing their pipeline, including the upcoming 26-week data from their second Phase III trial, COMP006, anticipated in the second half of 2026.

Successful Phase III Trial Results

COMPASS Pathways announced the successful achievement of the primary endpoint of the COMP360, 005 trial, demonstrating a clinically meaningful reduction in depression with no unexpected safety findings.

Positive Data from Multiple Studies

COMPASS has delivered positive, statistically significant results from two robust late-stage studies with over 230 patients each, providing important clinical validation for COMP360 treatment potential in TRD.

Strong Financial Position

The company had cash and cash equivalents of $222 million at the end of June, expected to fund operations into 2027.

Expansion into PTSD

COMPASS is in the final steps of designing a late-stage clinical program in PTSD, seeing significant commercial opportunity given the high unmet need.

COMPASS Pathways (CMPS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CMPS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.40 / -	-0.56	―	―	―
Jul 31, 2025	2025 (Q2)	-0.43 / -0.41	-0.56	26.79% (+0.15)	―
May 08, 2025	2025 (Q1)	-0.47 / -0.24	-0.55	56.36% (+0.31)	―
Feb 27, 2025	2024 (Q4)	-0.63 / -0.63	-0.53	-18.87% (-0.10)	―
Oct 31, 2024	2024 (Q3)	-0.57 / -0.56	-0.67	16.42% (+0.11)	―
Aug 01, 2024	2024 (Q2)	-0.54 / -0.56	-0.62	9.68% (+0.06)	―
May 08, 2024	2024 (Q1)	-0.48 / -0.55	-0.57	3.51% (+0.02)	―
Feb 29, 2024	2023 (Q4)	-0.36 / -0.53	-0.73	27.40% (+0.20)	―
Nov 02, 2023	2023 (Q3)	-0.52 / -0.67	-0.43	-55.81% (-0.24)	―
Aug 03, 2023	2023 (Q2)	-0.71 / -0.62	-0.5	-24.00% (-0.12)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CMPS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$3.94	$4.35	+10.41%
May 08, 2025	$3.74	$3.76	+0.53%
Feb 27, 2025	$3.70	$3.92	+5.95%
Oct 31, 2024	$6.19	$4.76	-23.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does COMPASS Pathways (CMPS) report earnings?

COMPASS Pathways (CMPS) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is COMPASS Pathways (CMPS) earnings time?

COMPASS Pathways (CMPS) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CMPS EPS forecast?

CMPS EPS forecast for the fiscal quarter 2025 (Q3) is -0.4.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing